Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China 2023-03-31 10:00
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2022 2023-03-31 07:30
NADclinic Group, BioStarks and Do Not Age Announce Exclusive Partnership to Revolutionise Personalised Longevity 2023-03-31 03:03
Croma-Pharma: Further strengthening its portfolio with PhilArt biostimulators 2023-03-31 00:33
HistoSonics Announces First Ever Kidney Tumor Treatment Using Histotripsy 2023-03-30 22:12
DISCOVERY LIFE SCIENCES INSTALLS WORLD'S LARGEST COMMERCIAL FLEET OF NOVASEQ X PLUS SYSTEMS TO ACCELERATE GENOMIC RESEARCH WITH UNPRECEDENTED SPEED AND COST EFFICIENCY 2023-03-30 21:05
IMG Travel Outlook Survey Predicts Continued Surge of International Travel in 2023 2023-03-30 21:00
ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization 2023-03-30 20:51
Turn Biotechnologies Introduces its Dermatology Platform to the European Aesthetic Community at AMWC 2023-03-30 20:00
DxVx Co., Ltd.'s affiliated company, Oxford Vacmedix (OVM) successfully completed Phase 1a in clinical trial of novel cancer vaccine OVM-200 2023-03-30 17:39
Great Place To Work unveils Best Workplaces in the Inaugural Singapore Healthcare and Biopharma List 2023 2023-03-30 12:00
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients 2023-03-30 08:00
Zimmer Biomet's ROSA HIP with ONE Planner Hip Awarded Orthopaedic Product Innovation of the Year by Healthcare Asia Medtech Awards 2023 2023-03-30 08:00
Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063 2023-03-30 03:32
Broncus Medical (02216.HK) Announces Annual Results for 2022 2023-03-30 01:05
PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy 2023-03-29 22:53
LifeTech Reports Steady Growth of 32.5percent in Net Profit Attributable to Owners of the Company in 2022 2023-03-29 22:21
BGI Genomics Partners with Zentya to Launch Fecal DNA Test for Colorectal Cancer in Slovakia 2023-03-29 16:00
Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer 2023-03-29 14:00
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia 2023-03-29 08:30
1 121 122 123 124 125 532